Ultrasound imaging technology developer Targeson is receiving funding from the U.S. National Institutes of Health (NIH) for its kidney disease therapy initiative.
The project will explore how therapeutic substances can be delivered to the kidney by ultrasound using Targeson's microbubble platform as a high-efficiency targeted contrast agent, according to the San Diego-based vendor.
Related Reading
Targeson lands SBIR funding, March 30, 2010
Targeson moves to San Diego, December 16, 2009
Targeson launches US contrast agent, August 26, 2009
Targeson debuts US contrast agent, August 11, 2009
Copyright © 2010 AuntMinnie.com